about
Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implicationsUric acid in metabolic syndrome: From an innocent bystander to a central playerHyperuricaemia with deposition: latest evidence and therapeutic approachMolecular Characterization of Reactive Oxygen Species in Myocardial Ischemia-Reperfusion InjuryReview: Gout: A Roadmap to Approaches for Improving Global OutcomesRole of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic SteatohepatitisA review of uric acid, crystal deposition disease, and gout.Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment optionsAllopurinol initiation and all-cause mortality in the general population.Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims.Factors associated with initiation and persistence of urate-lowering therapy.Investigational drugs for hyperuricemia.Xanthine oxidase inhibitors in ischaemic heart disease.Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.Uric acid and cardiovascular risk: What genes can say.Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.Cardiac and renal protective effects of urate-lowering therapy.Gout and Metabolic Syndrome: a Tangled Web.A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting.Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease
P2860
Q26738948-7B166C1C-5DB3-4BF1-AAAD-935A964C95D3Q26772053-C8BF8DCB-F8B1-4522-AFF0-945B3B10A52DQ26775759-7A201D65-4BDA-40CE-97B0-3BA337995876Q26778211-D33A9DF6-A43C-421C-B0F9-BB6E9107D3E7Q28076018-C6F07AF6-2DE7-4AAD-BF53-B68A777BF31AQ28354735-AECF6B54-DDF0-4562-AF47-6CFA628FA661Q30619265-83DDB5DE-C998-4D72-B041-552306EB13A0Q33864537-064C66C5-FED4-4148-A174-E31805F58C9AQ34466066-A26001F0-ECA6-4814-9455-CDDAF1BFC005Q35642254-AC42D88A-66A7-4AF2-AA36-BE8E37C52D91Q36306524-34738D34-57C5-45E5-9B9D-CFF67C922D9FQ37127097-0F999981-002E-4EB4-B8A8-64D85A9F1DAAQ37251800-4D0A22AA-279C-4A8D-8F18-5DB332487545Q37308677-C10D6796-179B-436A-9D42-3665B17534D8Q37589104-FD9DD392-C08E-4AFA-B80B-894BF5648276Q38527441-30D25C68-6F86-43D1-BD81-0425BC91CB2CQ39324330-10611978-3BC5-4052-908E-A476E0E20B9EQ47594590-6FD8B087-EE3D-4119-898D-80DD47200E07Q48102504-CA32F7BF-E6CA-4C5C-81BD-724D05B32E46Q49584618-634F2C0A-88E6-4F19-8BEC-36FA6E1CD83EQ49616077-385BCF71-6E7B-4E75-BFD2-68EDFC6BE0A7Q52534066-2DAEC7DA-C954-45AC-949F-A33616EA0F35Q55619193-678BB630-60CF-4772-BA0E-E6BBCFBE660EQ58129718-CFE5CCA7-91F9-4802-9A71-216B32CE88A6
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Impact of allopurinol on risk of myocardial infarction.
@en
Impact of allopurinol on risk of myocardial infarction.
@nl
type
label
Impact of allopurinol on risk of myocardial infarction.
@en
Impact of allopurinol on risk of myocardial infarction.
@nl
prefLabel
Impact of allopurinol on risk of myocardial infarction.
@en
Impact of allopurinol on risk of myocardial infarction.
@nl
P2093
P2860
P1476
Impact of allopurinol on risk of myocardial infarction.
@en
P2093
A Alpérovitch
L Abenhaim
M Rossignol
PGRx MI Group
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-202972
P407
P577
2014-01-06T00:00:00Z